AbbVie Inc (ABBV)vsVivos Therapeutics Inc (VVOS)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
VVOS
Vivos Therapeutics Inc
$0.80
+2.26%
HEALTHCARE · Cap: $11.46M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 350528% more annual revenue ($61.16B vs $17.44M). ABBV leads profitability with a 6.9% profit margin vs -121.4%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
VVOS
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+57.9%
Fair Value
$3.68
Current Price
$0.80
$2.88 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
3.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -663.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : VVOS
The strongest argument for VVOS centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : VVOS
The primary concerns for VVOS are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while VVOS is a turnaround play — different risk/reward profiles.
VVOS carries more volatility with a beta of 6.90 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 23/100). VVOS offers better value entry with a 57.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Vivos Therapeutics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?